Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polymorphism, Single Nucleotide | 16 | 2019 | 52 | 1.340 |
Why?
|
Genome, Human | 10 | 2013 | 27 | 0.970 |
Why?
|
Fibrosis | 2 | 2024 | 14 | 0.940 |
Why?
|
Oligonucleotide Array Sequence Analysis | 11 | 2008 | 32 | 0.780 |
Why?
|
Genetic Variation | 6 | 2019 | 36 | 0.740 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2019 | 8 | 0.650 |
Why?
|
Biomarkers, Tumor | 2 | 2019 | 19 | 0.650 |
Why?
|
Humans | 27 | 2024 | 5485 | 0.620 |
Why?
|
Selection, Genetic | 3 | 2010 | 44 | 0.600 |
Why?
|
Melanoma | 2 | 2024 | 30 | 0.600 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 3 | 0.590 |
Why?
|
Work Performance | 1 | 2018 | 2 | 0.590 |
Why?
|
Surgeons | 1 | 2018 | 6 | 0.590 |
Why?
|
Laminectomy | 2 | 2024 | 2 | 0.590 |
Why?
|
Clinical Competence | 1 | 2018 | 14 | 0.590 |
Why?
|
Freezing | 2 | 2024 | 4 | 0.550 |
Why?
|
Music | 1 | 2018 | 42 | 0.550 |
Why?
|
Protein Phosphatase 2 | 1 | 2024 | 1 | 0.480 |
Why?
|
Myofibroblasts | 1 | 2024 | 7 | 0.480 |
Why?
|
Altitude | 3 | 2010 | 4 | 0.480 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2024 | 11 | 0.470 |
Why?
|
Amino Acid Substitution | 1 | 2024 | 17 | 0.470 |
Why?
|
Extracellular Traps | 1 | 2024 | 3 | 0.470 |
Why?
|
Chromosome Mapping | 5 | 2007 | 13 | 0.470 |
Why?
|
Macrophages | 1 | 2024 | 29 | 0.470 |
Why?
|
Magnesium | 1 | 2024 | 7 | 0.470 |
Why?
|
Hydrogen | 1 | 2024 | 15 | 0.460 |
Why?
|
Hydrogels | 1 | 2024 | 15 | 0.460 |
Why?
|
Boron | 1 | 2024 | 1 | 0.450 |
Why?
|
Water Purification | 1 | 2024 | 3 | 0.450 |
Why?
|
Anxiety | 2 | 2023 | 173 | 0.440 |
Why?
|
Algorithms | 5 | 2006 | 275 | 0.440 |
Why?
|
Atrazine | 1 | 2023 | 1 | 0.440 |
Why?
|
Lakes | 1 | 2023 | 3 | 0.430 |
Why?
|
Water Pollutants, Chemical | 1 | 2023 | 15 | 0.430 |
Why?
|
Acupuncture Therapy | 1 | 2023 | 1 | 0.420 |
Why?
|
Sequence Analysis, DNA | 4 | 2006 | 27 | 0.420 |
Why?
|
Disease Models, Animal | 1 | 2024 | 242 | 0.410 |
Why?
|
Signal Transduction | 1 | 2024 | 225 | 0.410 |
Why?
|
Vestibular Neuronitis | 1 | 2022 | 1 | 0.410 |
Why?
|
Depression, Postpartum | 1 | 2022 | 3 | 0.410 |
Why?
|
Mindfulness | 1 | 2022 | 10 | 0.400 |
Why?
|
Quality of Life | 3 | 2022 | 117 | 0.380 |
Why?
|
DNA Mutational Analysis | 3 | 2006 | 8 | 0.370 |
Why?
|
Mice | 5 | 2024 | 719 | 0.370 |
Why?
|
Nanoparticles | 1 | 2021 | 74 | 0.350 |
Why?
|
Neoplasms | 2 | 2019 | 99 | 0.340 |
Why?
|
Adenoma | 1 | 2019 | 2 | 0.330 |
Why?
|
Circulating Tumor DNA | 1 | 2019 | 1 | 0.330 |
Why?
|
Gene Expression Profiling | 3 | 2010 | 55 | 0.330 |
Why?
|
Biological Assay | 1 | 2019 | 33 | 0.330 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 14 | 0.330 |
Why?
|
B7-H1 Antigen | 1 | 2019 | 5 | 0.330 |
Why?
|
Female | 8 | 2024 | 2816 | 0.320 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 10 | 0.320 |
Why?
|
Lung Neoplasms | 1 | 2019 | 27 | 0.310 |
Why?
|
Genetics, Population | 4 | 2010 | 15 | 0.310 |
Why?
|
Male | 7 | 2024 | 2770 | 0.300 |
Why?
|
Genotype | 9 | 2013 | 58 | 0.300 |
Why?
|
Sequence Alignment | 3 | 2005 | 20 | 0.290 |
Why?
|
Animals | 5 | 2024 | 1817 | 0.290 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2007 | 1 | 0.290 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2007 | 1 | 0.290 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2007 | 1 | 0.290 |
Why?
|
Models, Genetic | 4 | 2007 | 31 | 0.280 |
Why?
|
Gene Dosage | 3 | 2008 | 9 | 0.270 |
Why?
|
Genetic Testing | 4 | 2008 | 6 | 0.260 |
Why?
|
Epidemiologic Studies | 1 | 2005 | 1 | 0.260 |
Why?
|
Social Environment | 1 | 2005 | 15 | 0.250 |
Why?
|
Cell Line, Tumor | 3 | 2021 | 175 | 0.240 |
Why?
|
Aged | 4 | 2024 | 860 | 0.240 |
Why?
|
Epidural Space | 2 | 2024 | 2 | 0.240 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2024 | 5 | 0.230 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 16 | 0.230 |
Why?
|
Pyridines | 1 | 2024 | 24 | 0.230 |
Why?
|
Schistosomiasis | 1 | 2013 | 1 | 0.220 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 5 | 0.220 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 15 | 0.220 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 195 | 0.220 |
Why?
|
Transcriptome | 1 | 2013 | 47 | 0.210 |
Why?
|
Indians, North American | 2 | 2009 | 2 | 0.200 |
Why?
|
Middle Aged | 4 | 2024 | 1100 | 0.200 |
Why?
|
Databases, Genetic | 1 | 2010 | 8 | 0.180 |
Why?
|
Genomics | 3 | 2019 | 44 | 0.180 |
Why?
|
Reactive Oxygen Species | 2 | 2024 | 35 | 0.180 |
Why?
|
Chromosomes, Human, X | 3 | 2006 | 4 | 0.180 |
Why?
|
Reproducibility of Results | 6 | 2019 | 350 | 0.170 |
Why?
|
Hypoxia | 2 | 2009 | 12 | 0.170 |
Why?
|
Chromosomes, Human | 3 | 2013 | 5 | 0.170 |
Why?
|
Competitive Behavior | 1 | 2018 | 1 | 0.150 |
Why?
|
Performance Anxiety | 1 | 2018 | 2 | 0.150 |
Why?
|
Adult | 4 | 2024 | 1687 | 0.150 |
Why?
|
Aged, 80 and over | 2 | 2019 | 321 | 0.150 |
Why?
|
Asthma | 2 | 2008 | 11 | 0.140 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1 | 0.130 |
Why?
|
Genetics, Medical | 1 | 2005 | 1 | 0.120 |
Why?
|
Virus Internalization | 1 | 2024 | 7 | 0.120 |
Why?
|
DNA | 3 | 2008 | 65 | 0.120 |
Why?
|
Antibodies, Viral | 1 | 2024 | 14 | 0.120 |
Why?
|
Neutrophils | 1 | 2024 | 19 | 0.120 |
Why?
|
Penicillins | 1 | 2004 | 2 | 0.110 |
Why?
|
Gene Frequency | 4 | 2007 | 19 | 0.110 |
Why?
|
Alleles | 4 | 2007 | 20 | 0.110 |
Why?
|
Ampicillin | 1 | 2004 | 3 | 0.110 |
Why?
|
Cell Differentiation | 1 | 2024 | 75 | 0.110 |
Why?
|
Ofloxacin | 1 | 2004 | 5 | 0.110 |
Why?
|
Transcription, Genetic | 1 | 2004 | 18 | 0.110 |
Why?
|
Cold Temperature | 1 | 2024 | 4 | 0.110 |
Why?
|
Seawater | 1 | 2024 | 3 | 0.110 |
Why?
|
Salinity | 1 | 2024 | 8 | 0.110 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2004 | 32 | 0.110 |
Why?
|
United States | 2 | 2007 | 522 | 0.110 |
Why?
|
Herbicides | 1 | 2023 | 3 | 0.110 |
Why?
|
Mutation | 1 | 2024 | 137 | 0.110 |
Why?
|
Endometrium | 1 | 2023 | 1 | 0.110 |
Why?
|
Models, Chemical | 1 | 2023 | 35 | 0.110 |
Why?
|
Hormones | 1 | 2023 | 5 | 0.110 |
Why?
|
Dizziness | 1 | 2022 | 1 | 0.100 |
Why?
|
Pregnancy | 1 | 2023 | 103 | 0.100 |
Why?
|
Infant, Newborn | 1 | 2022 | 49 | 0.100 |
Why?
|
Gene Expression | 1 | 2002 | 52 | 0.100 |
Why?
|
Escherichia coli | 1 | 2004 | 111 | 0.100 |
Why?
|
Health Promotion | 1 | 2022 | 39 | 0.100 |
Why?
|
Naphthoquinones | 1 | 2021 | 1 | 0.100 |
Why?
|
Delayed-Action Preparations | 1 | 2021 | 5 | 0.100 |
Why?
|
Sensitivity and Specificity | 4 | 2006 | 135 | 0.100 |
Why?
|
Mice, Nude | 1 | 2021 | 24 | 0.100 |
Why?
|
Anxiety Disorders | 1 | 2023 | 71 | 0.100 |
Why?
|
Drug Carriers | 1 | 2021 | 9 | 0.100 |
Why?
|
Particle Size | 1 | 2021 | 43 | 0.100 |
Why?
|
Risk Factors | 1 | 2022 | 184 | 0.090 |
Why?
|
Emigration and Immigration | 2 | 2005 | 8 | 0.090 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 183 | 0.090 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2019 | 1 | 0.080 |
Why?
|
Proof of Concept Study | 1 | 2019 | 7 | 0.080 |
Why?
|
Colonoscopy | 1 | 2019 | 3 | 0.080 |
Why?
|
Neoplasm Staging | 1 | 2019 | 9 | 0.080 |
Why?
|
ROC Curve | 1 | 2019 | 31 | 0.080 |
Why?
|
Colon | 1 | 2019 | 8 | 0.080 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 5 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 6 | 0.080 |
Why?
|
Healthy Volunteers | 1 | 2019 | 42 | 0.080 |
Why?
|
False Negative Reactions | 1 | 2019 | 2 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2019 | 30 | 0.080 |
Why?
|
Prognosis | 1 | 2019 | 59 | 0.080 |
Why?
|
Computational Biology | 1 | 2019 | 42 | 0.080 |
Why?
|
Prospective Studies | 1 | 2019 | 132 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 36 | 0.080 |
Why?
|
Lung | 1 | 2019 | 42 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 55 | 0.080 |
Why?
|
Population Groups | 1 | 2008 | 1 | 0.080 |
Why?
|
Haplotypes | 1 | 2008 | 12 | 0.080 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2008 | 1 | 0.080 |
Why?
|
Phylogeny | 2 | 2010 | 66 | 0.070 |
Why?
|
Linkage Disequilibrium | 1 | 2006 | 1 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2006 | 2 | 0.070 |
Why?
|
Genetic Markers | 2 | 2007 | 10 | 0.070 |
Why?
|
Benzo(a)pyrene | 1 | 2005 | 2 | 0.060 |
Why?
|
Deoxyguanosine | 1 | 2005 | 2 | 0.060 |
Why?
|
History, 16th Century | 1 | 2005 | 1 | 0.060 |
Why?
|
History, 17th Century | 1 | 2005 | 2 | 0.060 |
Why?
|
Pedigree | 1 | 2005 | 7 | 0.060 |
Why?
|
Latin America | 1 | 2005 | 6 | 0.060 |
Why?
|
DNA Damage | 1 | 2005 | 11 | 0.060 |
Why?
|
Regression Analysis | 1 | 2005 | 31 | 0.060 |
Why?
|
Ultraviolet Rays | 1 | 2005 | 30 | 0.060 |
Why?
|
Mucous Membrane | 1 | 2024 | 1 | 0.060 |
Why?
|
DNA Primers | 1 | 2004 | 17 | 0.060 |
Why?
|
Regulatory Sequences, Ribonucleic Acid | 1 | 2013 | 1 | 0.060 |
Why?
|
RNA Probes | 1 | 2003 | 1 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2013 | 26 | 0.050 |
Why?
|
Phenotype | 1 | 2013 | 73 | 0.050 |
Why?
|
Genetic Linkage | 2 | 2007 | 5 | 0.050 |
Why?
|
Globins | 1 | 2010 | 1 | 0.040 |
Why?
|
South America | 1 | 2010 | 1 | 0.040 |
Why?
|
Tibet | 1 | 2010 | 1 | 0.040 |
Why?
|
Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2010 | 2 | 0.040 |
Why?
|
Procollagen-Proline Dioxygenase | 1 | 2010 | 4 | 0.040 |
Why?
|
DNA Copy Number Variations | 1 | 2010 | 9 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 7 | 0.040 |
Why?
|
Geography | 1 | 2010 | 7 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2010 | 11 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 32 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2009 | 13 | 0.040 |
Why?
|
DNA Probes | 2 | 2004 | 10 | 0.040 |
Why?
|
Indians, Central American | 1 | 2007 | 1 | 0.040 |
Why?
|
Indians, South American | 1 | 2007 | 1 | 0.040 |
Why?
|
Population | 1 | 2005 | 1 | 0.030 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2004 | 2 | 0.030 |
Why?
|
Software | 1 | 2005 | 59 | 0.030 |
Why?
|
Regulon | 1 | 2004 | 1 | 0.030 |
Why?
|
Phosphates | 1 | 2004 | 3 | 0.030 |
Why?
|
Polysaccharides | 1 | 2004 | 3 | 0.030 |
Why?
|
RNA, Bacterial | 1 | 2004 | 15 | 0.030 |
Why?
|
Computer Simulation | 1 | 2005 | 187 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2004 | 99 | 0.030 |
Why?
|
Bacterial Proteins | 1 | 2004 | 57 | 0.030 |
Why?
|
Yeasts | 1 | 2002 | 2 | 0.030 |
Why?
|
Quality Control | 1 | 2002 | 6 | 0.030 |
Why?
|
Stochastic Processes | 1 | 2002 | 7 | 0.030 |
Why?
|
Models, Statistical | 1 | 2002 | 70 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2002 | 69 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 77 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2008 | 38 | 0.020 |
Why?
|
Puerto Rico | 1 | 2008 | 5 | 0.020 |
Why?
|
Benzopyrenes | 1 | 2005 | 1 | 0.020 |
Why?
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1 | 2005 | 1 | 0.020 |
Why?
|
Singlet Oxygen | 1 | 2005 | 1 | 0.020 |
Why?
|
Microsomes | 1 | 2005 | 6 | 0.020 |
Why?
|
Superoxides | 1 | 2005 | 6 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 7 | 0.020 |
Why?
|
Child | 1 | 2008 | 657 | 0.010 |
Why?
|
Candidiasis, Chronic Mucocutaneous | 1 | 2004 | 1 | 0.010 |
Why?
|
Thyroid Diseases | 1 | 2004 | 1 | 0.010 |
Why?
|
Heterozygote | 1 | 2004 | 9 | 0.010 |
Why?
|
Adolescent | 1 | 2008 | 806 | 0.010 |
Why?
|
Research Design | 1 | 2004 | 35 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2004 | 20 | 0.010 |
Why?
|
Open Reading Frames | 1 | 2003 | 4 | 0.010 |
Why?
|
Biomarkers | 1 | 2004 | 87 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 86 | 0.010 |
Why?
|
Models, Molecular | 1 | 2003 | 87 | 0.010 |
Why?
|